Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1

Diabetes, Obesity and Metabolism

Volumn 7, Issue 5, 2005, Pages 563-569

  Green, B D ^a   Liu, H K ^b   McCluskey, J T ^a   Duffy, N A ^a   O'Harte, F P M ^a   McClenaghan, N H ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

DPP IV; GLP 1 analogues; Glucagon like peptid 1 (GLP 1); Insulin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; DRUG METABOLITE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCOSE; INSULIN; N ACETYLGLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME DEGRADATION; ENZYME INHIBITION; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; RECEPTOR DOWN REGULATION;

EID: 23844458304     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00430.x     Document Type: Article

References (33)

1. Drucker DJ. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 2001; 7: 1399-1412.
2. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.
3. Flamez D, Gilon P, Moens K et al. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999; 48: 1979-1986.
4. Farilla L, Hui H, Bertolotto C et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
5. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
6. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
7. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-1258.
8. Pauly RP, Demuth HU, Rosche F et al. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 1999; 48: 385-389.
9. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
10. O'Harte FPM, Mooney MH, Kelly CM, McKillop AM, Flatt PR. Degradation and glycemic effects of His (7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Regul Pept 2001; 96: 95-104.
11. Mooney MH, Abdel-Wahab YHA, McKillop AM, O'Harte FPM, Flatt PR. Evaluation of glycated glucagon-like peptide-1(7-36) amide in intestinal tissue of normal and diabetic animal models. Biochim Biophys Acta 2002; 1569: 75-80.
12. Green BD, Gault VA, Mooney MH et al. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 (7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003; 31: 529-540.
13. 9-substituted analogues of glucagon-like peptide-1. Biol Chem 2003; 384: 1543-1551.
14. Green BD, Mooney MH, Gault VA et al. N-terminal His 7-modification of GLP-1 generates DPP IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004; 180: 379-388.
15. 9 substitution in glucagon-like peptide-1(7-36)amide (GLP-1) confers DPP IV resistance with cellular and metabolic actions similar to those of established antagonists GLP-1(9-36)amide and exendin (9-39). Metabolism 2004; 53: 252-259.
16. 8-substituted GLP-1 analogues. Biol Chem 2004; 385: 169-177.
17. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
18. Zhou J, Pineyro MA, Wang X, Doyle ME, Egan JM. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 2002; 192: 304-314.
19. Gromada J, Dissing S, Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms. Br J Pharmacol 1996; 118: 769-775.
20. Widmann C, Dolci W, Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol 1996; 10: 62-75.
21. Liu H-K, Green BD, Gault VA, McClenaghan NH, McCluskey JT, Flatt PR. N-acetyl-GLP-1: a DPP IV resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell associated gene expression. Cell Biol Int 2004; 28: 69-73.
22. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990; 35: 161-214.
23. McClenaghan NH, Barnett CR, Ah-Sing E et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996; 45: 1132-1140.
24. Fujiwara K, Tsuru D. New chromogenic and fluorogenic substrates for pyrrolidonyl peptidase. J Biochem 1978; 83: 1145-1149.
25. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in hoterozygous lean (ob/+) mice. Diabetologia 1981; 20: 573-577.
26. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438.
27. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600-4605.
28. Xiao Q, Giguere J, Parisien M et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40: 2860-2869.
29. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR. Glycation of glucagon-like peptide-1 (7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 1998; 41: 1187-1193.
30. O'Harte FPM, Gault VA, Parker JC et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and Pglu-GIP. Diabetologia 2002; 45: 1281-1291.
31. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429-435.
32. Miguel JC, Abdel-Wahab YHA, Green BD, Mathias PC, Flatt PR. Cooperative enhancement of insulinotropic action GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity. Biochem Pharmacol 2003; 65: 283-292.
33. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8: 179-188.